At a glance
ClinicalIndex Comparison RecordN/ACompleted· 200 enrolled
Drug / intervention
nepafenac 0.3% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%
In Brief
A clinical study evaluating nepafenac 0.3% and ketorolac for Cataract. Completed, enrolled 200 participants across 2 sites.
Detailed Summary
This study will examine the tolerability and toxicity of topically applied Nepafenac 0.3% vs ketorolac 0.5% among patients undergoing cataract surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
CollaboratorsAlcon Research
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedApr 2016
Primary CompletionMar 2017
TodayJul 2026
First PostedApr 27, 2016
Enrollment StartApr 1, 2016
Primary CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.2 years ago
Interventions
nepafenac 0.3%drug
Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
ketorolacdrug
Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.